Menarini Silicon Biosystems
Muthu Meyyappan serves as the Global Chief Commercial Officer at Menarini Silicon Biosystems since May 2022, focusing on transforming the Oncology business unit's commercial strategy and enhancing the adoption of the FDA-approved CellSearch® liquid biopsy test. Previously, Muthu held the position of Chief Commercial Officer at Congenica, driving global sales and marketing for a CE-IVD NGS SaaS platform, and at Variantyx, leading the commercial launch of whole genome testing services. Muthu has also held various leadership roles at QIAGEN, including Vice President of Advanced Genomics Commercial Operations, where significant revenue growth was achieved, and at BIOBASE Corporation, where a commercial operations organization was established. Early career roles included positions at Incyte Corporation and Wyeth-Ayerst Research, underscoring a strong background in life sciences and biotechnology, supported by a Ph.D. in Cancer Biology from the University of Calgary and a B.S. in Biotechnology from the Rochester Institute of Technology.
This person is not in any offices
Menarini Silicon Biosystems
1 followers
Menarini Silicon Biosystems offers unique rare cell technologies and solutions that provide clinical researchers with access to unparalleled resolution in the study of cells and their molecular characterization. The company’s CELLSEARCH® and DEPArray™ technologies together provide an end-to-end solution for enumeration and sorting of rare cells with single-cell precision. Menarini Silicon Biosystems, based in Bologna, Italy, and Huntingdon Valley, PA, US, is a wholly-owned subsidiary of the Menarini Group, a multinational pharmaceutical, biotechnology, and diagnostics company headquartered in Florence, Italy, with 17,640 employees in 136 countries. Read our Netiquette here: www.siliconbiosystems.com/netiquette